Shanghai Haohai Biological Technology Co., Ltd. (HKG:6826)

Market Cap	11.68B
Revenue (ttm)	2.87B
Net Income (ttm)	447.12M
Shares Out	228.73M
EPS (ttm)	1.37
PE Ratio	17.91
Forward PE	9.48
Dividend	0.85 (3.50%)
Ex-Dividend Date	Sep 20, 2024

Volume	202,380
Average Volume	381,393
Open	24.50
Previous Close	24.50
Day's Range	24.00 - 24.70
52-Week Range	21.70 - 42.95
Beta	0.58
RSI	42.41
Earnings Date	Apr 25, 2025

About HKG:6826

Shanghai Haohai Biological Technology Co., Ltd. engages in the research, development, manufacture, and sale of biomedical materials in China, Europe, the United States, and internationally. The company offers ophthalmology products consisting intraocular lens, medical sodium hyaluronate gel, and lubricant eye drop. It also offers sodium hyaluronate injection, medical chitosan, sodium hyaluronate gel, sodium hyaluronate gel, anti adhesion, and burn wound related products. In addition, the company provides injectors, scalpels, and suture needles....

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2007
• Employees: 2,158
• Stock Exchange: Hong Kong Stock Exchange
• Ticker Symbol: 6826

Financial Performance

In 2024, HKG:6826's revenue was 2.70 billion, an increase of 1.64% compared to the previous year's 2.65 billion. Earnings were 420.15 million, an increase of 0.97%.

Financial numbers in CNY